A Comparison of 18F-PSMA-1007 and 64Cu-PSMA in 2 Patients With Metastatic Prostate Cancer

David R. Cardoza-Ochoa; Belén Rivera-Bravo

doi:10.1097/RLU.0000000000003758

A Comparison of ¹⁸F-PSMA-1007 and ⁶⁴Cu-PSMA in 2 Patients With Metastatic Prostate Cancer

David R. Cardoza-Ochoa, Belén Rivera-Bravo

Research output: Contribution to journal › Article › peer-review

Abstract

18F-prostate-specific membrane antigen (PSMA) 1007 is one of the most promising radiotracers for PET imaging in prostate cancer, minimal urinary clearance, and higher spatial resolution, which are the most outstanding features. PSMA can also be labeled with 64Cu, offering a longer half-life and different resolution imaging. We present images of metastatic prostate cancer in two patients, where 64Cu-PSMA PET/CT was performed one day after 18F-PSMA-1007 PET/CT. In the two patients, both radiotracers provided high image quality and a similar range of detection for metastatic lesions.

Original language	English (US)
Pages (from-to)	E120-E122
Journal	Clinical Nuclear Medicine
Volume	47
Issue number	2
DOIs	https://doi.org/10.1097/RLU.0000000000003758
State	Published - Feb 1 2022
Externally published	Yes

Keywords

F-PSMA
Cu-PSMA
prostate cancer

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/RLU.0000000000003758

Cite this

@article{16300688046b44b29bb61dfecadf2cb5,

title = "A Comparison of 18F-PSMA-1007 and 64Cu-PSMA in 2 Patients With Metastatic Prostate Cancer",

abstract = "18F-prostate-specific membrane antigen (PSMA) 1007 is one of the most promising radiotracers for PET imaging in prostate cancer, minimal urinary clearance, and higher spatial resolution, which are the most outstanding features. PSMA can also be labeled with 64Cu, offering a longer half-life and different resolution imaging. We present images of metastatic prostate cancer in two patients, where 64Cu-PSMA PET/CT was performed one day after 18F-PSMA-1007 PET/CT. In the two patients, both radiotracers provided high image quality and a similar range of detection for metastatic lesions.",

keywords = "F-PSMA, Cu-PSMA, prostate cancer",

author = "Cardoza-Ochoa, {David R.} and Bel{\'e}n Rivera-Bravo",

year = "2022",

month = feb,

day = "1",

doi = "10.1097/RLU.0000000000003758",

language = "English (US)",

volume = "47",

pages = "E120--E122",

journal = "Clinical Nuclear Medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - A Comparison of 18F-PSMA-1007 and 64Cu-PSMA in 2 Patients With Metastatic Prostate Cancer

AU - Cardoza-Ochoa, David R.

AU - Rivera-Bravo, Belén

PY - 2022/2/1

Y1 - 2022/2/1

N2 - 18F-prostate-specific membrane antigen (PSMA) 1007 is one of the most promising radiotracers for PET imaging in prostate cancer, minimal urinary clearance, and higher spatial resolution, which are the most outstanding features. PSMA can also be labeled with 64Cu, offering a longer half-life and different resolution imaging. We present images of metastatic prostate cancer in two patients, where 64Cu-PSMA PET/CT was performed one day after 18F-PSMA-1007 PET/CT. In the two patients, both radiotracers provided high image quality and a similar range of detection for metastatic lesions.

AB - 18F-prostate-specific membrane antigen (PSMA) 1007 is one of the most promising radiotracers for PET imaging in prostate cancer, minimal urinary clearance, and higher spatial resolution, which are the most outstanding features. PSMA can also be labeled with 64Cu, offering a longer half-life and different resolution imaging. We present images of metastatic prostate cancer in two patients, where 64Cu-PSMA PET/CT was performed one day after 18F-PSMA-1007 PET/CT. In the two patients, both radiotracers provided high image quality and a similar range of detection for metastatic lesions.

KW - F-PSMA

KW - Cu-PSMA

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85123174463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123174463&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000003758

DO - 10.1097/RLU.0000000000003758

M3 - Article

C2 - 34115708

AN - SCOPUS:85123174463

SN - 0363-9762

VL - 47

SP - E120-E122

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

IS - 2

ER -